Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus

Clinical Cancer Research

Volumn 12, Issue 21, 2006, Pages 6523-6531

  Zhang, Qi ^a,c   Chen, Guihua ^c   Peng, Linhui ^a   Wang, Xinghua ^a   Yang, Yang ^c   Liu, Chen ^a   Shi, Wenfang ^a   Su, Changqing ^a   Wu, Hongping ^a   Liu, Xinyuan ^b,d   Wu, Mengchao ^a   Qian, Qijun ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b ZHEJIANG SCI TECH UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CNHK 500; E1A PROTEIN; E1B PROTEIN; PROBIOTIC AGENT; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG SPECIFICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; ONCOLYTIC VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS REPLICATION; XENOGRAFT;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ADENOVIRUS E1B PROTEINS; ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; CELL LINE, TUMOR; DNA PRIMERS; GENE EXPRESSION; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS (GENETICS); TELOMERASE; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33751290743     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1491     Document Type: Article

References (42)

1. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005;40: 225-35.
2. Okuda K. Where we go with hepatocellular carcinoma: past, present, and future perspectives. J Hepatobiliary Pancreat Surg 2002;9:683-5.
3. Ring CJ. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002;83:491-502.
4. Smith ER, Chiocca EA. Oncolytic viruses as novel anticancer agents: turning one scourge against another. Expert Opin Investig Drugs 2000;9:311-27.
5. Kim O, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001;7:781-7.
6. Vile R, Ando D, Kirn D. The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider. Cancer Gene Ther 2002; 9:1062-7.
7. Ko D, Hawkins L, Yu DC. Development of transcriptionally regulated oncolytic adenoviruses. Oncogene 2005;24:7763-74.
8. McCormick F. Future prospects for oncolytic therapy. Oncogene 2005;24:7817-9.
9. Cohen EE, Rudin CM. ONYX-015. Onyx Pharmaceuticals. Curr Opin Investig Drugs 2001;2:1770-5.
10. McCormick F. Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther 2003;2: S157-60.
11. Chen L, Chen D, Manome Y, Dong Y, Fine HA, Kufe DW. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest 1995; 96:2775-82.
12. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997;57: 2559-63.
13. Yu DC, Chen Y, Dilley J, et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001;61: 517-25.
14. Kim J, Lee B, Kim JS, et al. Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in α-fetoprotein-producing human liver cancer cells. Cancer Lett 2002;180:23-32.
15. Mathis JM, Stoff-Khalili MA, Curiel DT. Oncolytic adenoviruses-selective retargeting to tumor cells. Oncogene 2005;24:7775-91.
16. Shay JW, Wright WE. Telomeres and telomerase: implications for cancer and aging. Radiat Res 2001; 155:188-93.
17. Hsu YH, Lin JJ. Telomere and telomerase as targets for anti-cancer and regeneration therapies. Acta Pharmacol Sin 2005;26:513-8.
18. Hewitson KS, Schofield CJ. The HIF pathway as a therapeutic target. Drug Discov Today 2004;9: 704-11.
19. Welsh SJ, Powis G. Hypoxia inducible factor as a cancer drug target. Curr Cancer Drug Targets 2003;3: 391-405.
20. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
21. Su CQ, Sham J, Xue HB. et al. Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells. J Cancer Res Clin Oncol 2004;130:591-603.
22. Liddle C, Goodwin BJ, Tapner M. Culture and transfection of mammalian primary hepatocytes and hepatocyte-derived cell lines. J Gastroenterol Hepatol 1998;13:855-8.
23. Curiel DT. The development of conditionally replicative adenoviruses for cancer therapy. Clin Cancer Res 2000;6:3395-9.
24. Post DE, Khuri FR, Simons JW, Van Meir EG. Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 2003;14:933-46.
25. Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003;22:2065-72.
26. Oosterhoff D, van Beusechem VW. Conditionally replicating adenoviruses as anticancer agents and ways to improve their efficacy. J Exp Ther Oncol 2004;4:37-57.
27. Li Y, Idamakanti N, Arroyo T, et al. Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models. Clin Cancer Res 2005;11:8845-55.
28. Kanerva A, Hemminki A. Adenoviruses for treatment of cancer. Ann Med 2005;37:33-43.
29. Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke MF. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther 2002;13:1737-50.
30. Binley K, Askham Z, Martin L, et al. Hypoxia-mediated tumour targeting. Gene Ther 2003;10:540-9.
31. Huang TG, Savontaus MJ, Shinozaki K, Sauter BV, Woo SL. Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther 2003;10:1241-7.
32. Kim E, Kim JH, Shin HY, et al. Ad-mTERT-819, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 2003;14:1415-28.
33. Cuevas Y, Hernandez-Alcoceba R, Aragones J, et al. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas. Cancer Res 2003;63:6877-84.
34. Wirth T, Zender L, Schulte B, et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 2003;63: 3181-8.
35. Post DE, Devi NS, Li Z, et al. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res 2004; 10:8603-12.
36. Cho WK, Seong YR, Lee YH, et al. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. Mol Ther 2004; 10:938-49.
37. Pipiya T, Sauthoff H, Huang YQ, et al. Hypoxia reduces adenoviral replication in cancer cells by down-regulation of viral protein expression. Gene Ther 2005;12:911-7.
38. Shen BH, Hermiston TW. Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene Ther 2005;12:902-10.
39. Wang Y, Thorne S, Hannock J, et al. A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses. Clin Cancer Res 2005;11:351-60.
40. Qian Q, Sham J, Che X, et al. Gene-viral vectors: a promising way to target tumor cells and express anti-cancer genes simultaneously. Chin Med J 2002;115: 1213-7.
41. Zhang Q, Nie M, Sham J, et al. Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene. Cancer Res 2004;64:5390-7.
42. Su C, Peng L, Sham J, et al. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-γ gene yields efficient antitumor activity in immunodeficient and immunocompetent mice. Mol Ther 2006;13:918-27.